Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

890101

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accident and Emergency Departments: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many A&E units closed in each constituency in each year between 2010 and 2016.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	137151
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Changes to the local NHS services are a matter for the local National Health Service, and form part of the commissioning process. This includes working with local people and with clinicians to ensure that changes are in the best interests of patients. Records of this activity are not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 137152 question first answered 26/04/2018 16:39:29 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

890102

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many hospitals closed in each constituency in each year between 2010 and 2016.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	137152
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Changes to the local NHS services are a matter for the local National Health Service, and form part of the commissioning process. This includes working with local people and with clinicians to ensure that changes are in the best interests of patients. Records of this activity are not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 137151 question first answered 26/04/2018 16:39:29 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

890072

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	European Medicines Agency
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 April 2018 to Question 136501, how the Government plans for the UK to participate in the European Medicines Agency during the transition period after the UK leaves the EU.
	tabling member constituency	Westmorland and Lonsdale
	tabling member printed	Tim Farron
	uin	137122
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>From 30 March 2019, the United Kingdom will no longer be a Member of the European Union. However, under the terms of the implementation period agreement regulatory standards and market access for all medicines will continue on current terms.</p><p> </p><p>Both sides agree that for the implementation period to function effectively, the UK will need to remain in step with the EU. In this context, the Withdrawal Agreement will be underpinned by a duty of good faith, with a Joint Committee in place enabling either side to raise issues or concerns. These arrangements will help ensure that the implementation period works properly for both sides.</p><p> </p><p>Common rules will remain in place and the UK may continue to participate in EU agencies and bodies where the presence of the United Kingdom is necessary and is in the interests of the EU, or where the discussion concerns acts addressed to the UK and its citizens. The exact nature of this participation will be a matter for further discussion.</p><p> </p><p>Regarding the future relationship, the Prime Minister's Mansion House speech outlined that we will also explore the terms on which the UK could remain part of the European Medicines Agency. While it would not be appropriate to pre-judge the outcome of the negotiations, we will discuss with the EU and Member States how best to continue cooperation in medicines regulation.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 26/04/2018 16:06:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1591 label Biography information for Tim Farron

886206

	registered interest
	date	18/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many women have joined the PrEP Impact trial to date.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	136401
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Since the start of the pre-exposure prophylaxis (PrEP) Impact trial in October 2017, the trial has recruited around 5,700 participants in 121 different clinics. Interim trial analysis, including reported gender of participants, will be available in winter 2018/19.</p><p> </p><p>To date, no assessment has been made of potential barriers to joining the PrEP Impact trial for women who are victims of domestic violence.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136402 question first answered 26/04/2018 10:31:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

886207

	registered interest
	date	18/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of potential barriers to joining the PrEP Impact trail for women who are victims of domestic violence.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	136402
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Since the start of the pre-exposure prophylaxis (PrEP) Impact trial in October 2017, the trial has recruited around 5,700 participants in 121 different clinics. Interim trial analysis, including reported gender of participants, will be available in winter 2018/19.</p><p> </p><p>To date, no assessment has been made of potential barriers to joining the PrEP Impact trial for women who are victims of domestic violence.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136401 question first answered 26/04/2018 10:31:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

890003

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Royal Liverpool University Hospital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent progress has been made on identifying a new contractor to complete the building of the new Royal Liverpool University Hospital after the collapse of Carillion; and if will he make a statement.
	tabling member constituency	Liverpool, Riverside
	tabling member printed	Mrs Louise Ellman
	uin	137055
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Private Finance Initiative (PFI) contract between the Royal Liverpool and Broadgreen University Hospitals NHS Trust and the PFI Project Company is still in place, which means that the Company is still contractually obliged to manage the project and find a construction firm or subcontractor who can continue the building work.</p><p> </p><p>The Royal Liverpool Hospital scheme is very well advanced. The PFI Project Company is continuing its discussions with their lenders and with other service and construction companies to assess how best to continue delivering the contract. Officials from the Department and NHS Improvement are continuing to work very actively with all the parties to ensure there are plans in place to keep the delay as short as possible and provide the best value for money solution for the trust and for the public sector as a whole.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 26/04/2018 16:37:54 answering member 4095 label Biography information for Steve Barclay
	tabling member	484 label Biography information for Dame Louise Ellman

890118

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to maintain competition in clinical trials after the UK leaves the EU.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	137168
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Government has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation, including clinical trials. Every Government department, including the Department of Health and Social Care, is planning to deliver a smooth exit under any scenario, which includes preparing the UK for the future economic partnership we hope to negotiate with the European Union, as well as the very unlikely scenario in which no mutually satisfactory agreement can be reached and the UK exits without a deal.</p><p> </p><p>If the clinical trials regulation comes into force during the implementation period, as it is currently expected to do in March 2020, it will apply to the UK. The withdrawal agreement and implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period. If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the EU regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The UK is already a preferred destination for EU and global clinical trials. The Government has been clear that it is in the interest of patients and the life sciences industry across Europe for the UK and EU to find a way to continue cooperation in the field of clinical trials, and for continued sharing of data and information, even if our precise relationship with the EU will by necessity change. As part of the Department’s Exiting the EU programme, officials are working to ensure appropriate coordination across a number of projects relating to research and clinical trials including workforce, regulations, funding and rare diseases.</p><p> </p><p>The National Institute for Health Research (NIHR) provides the support, expertise and facilities that the National Health Service needs to undertake world-leading clinical trials funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities and the Clinical Research Network. Through NIHR and its partners, and by close collaboration with the life sciences sector and industry, the Government will ensure that the UK remains one of the best places in the world for research, science and innovation.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:21:29 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4036 label Biography information for Luciana Berger

890119

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials: EU Law
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure continued access to the EU clinical trials portal and database after the UK leaves the EU.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	137169
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>If the Clinical Trials Regulation comes into force during the Implementation Period, as it is currently expected to in March 2020, it will apply to the United Kingdom. The Withdrawal Agreement and Implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period.</p><p> </p><p>If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the European Union regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The two key elements of the Regulation that are outside of the UK’s control, and this guarantee does not therefore cover, are the use of a shared central IT portal and database and participation in the single assessment model, both of which require a negotiated UK/EU agreement regarding UK involvement post-Brexit. We cannot pre-empt these negotiations, nor can we disadvantage the UK’s position in these negotiations by giving any further guarantees at this time.</p><p> </p><p>Regardless of the outcome of a Brexit deal and the application date of the Regulation, the UK is committed to offering a competitive service for clinical trial assessment. This covers regulatory approval from the Medicines and Health products Regulatory Agency (MHRA) as well as services from the Health Research Authority, ethics services, the National Institute for Health Research and the National Health Service. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p><p> </p><p>In the event that the UK is not part of the EU shared central IT portal and database and therefore trials to be run wholly or in part in the UK are not submitted through the EU portal, it will still be perfectly possible for sponsors to run multistate trials involving the UK. Sponsors would have to apply to the MHRA as well as to the EU concerned states. However, MHRA would take every effort to ensure that a parallel submission to the MHRA was as streamlined and efficient as possible and that we were able to match or better the European timeline for assessment. MHRA and UK ethics committees are already internationally recognised for their robust yet timely assessment of trial applications and the UK is currently one of the most competitive Member States for timelines.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:20:11 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4036 label Biography information for Luciana Berger

890120

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to support the maintenance of links between regulators, research ethics committees, researchers and the pharmaceutical industry in the UK and the European Medicines Agency after the UK leaves the EU.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	137170
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Department has always made clear its intention to retain a close working partnership with the European Union, in the interest of ensuring patients continue to have timely access to safe medicines and medical innovations. This includes maintaining a strong working relationship with the European Medicines Agency on all aspects of the life sciences sector.</p><p> </p><p>It is of mutual benefit for the EU to collaborate closely with such a well-developed life sciences market in the United Kingdom. Both sides will always be stronger by working in partnership.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:23:42 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4036 label Biography information for Luciana Berger

890121

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will negotiate a deal with the EU to allow mutual recognition agreements on the manufacture and distribution of investigational medicinal products and pharmacovigilance services after the UK leaves the EU.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	137171
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>From 30 March 2019, the United Kingdom will no longer be a Member of the European Union. However, under the terms of the implementation period agreement regulatory standards and market access for all medicines will continue on current terms.</p><p> </p><p>Regarding the future relationship, the Prime Minister’s Mansion House speech outlined that we will also explore the terms on which the UK could remain part of the European Medicines Agency. While it would not be appropriate to pre-judge the outcome of the negotiations, we will discuss with the EU and Member States how best to continue cooperation in medicines regulation more broadly, including manufacturing and distribution of investigational medicinal products and pharmacovigilance services.</p><p> </p><p>Our overall aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and continued sharing of data.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 26/04/2018 16:07:42 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4036 label Biography information for Luciana Berger